A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Conditions: Multiple Myeloma; Monoclonal Gammopathy of Renal Significance Interventions: Drug: Cyclophosphamide; Drug: Bortezomib; Drug: Dexamethasone; Drug: Daratumumab Sponsors: Memorial Sloan Kettering Cancer Center; Janssen Pharmaceuticals Not yet recruiting

https://clinicaltrials.gov/study/NCT06083922

Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials